The ameliorative effects of thymoquinone and beta-aminoisobutyric acid on streptozotocin-induced diabetic cardiomyopathy

• Published in: Tissue & cell 2021-08, Vol.71, p.101582-101582, Article 101582
• Main Authors: Gur, Fatih Mehmet, Aktas, Ibrahim
• Format: Article
• Language: English
• Subjects: Aminoisobutyric Acids - pharmacology; Animals; Antioxidants; Apoptosis; Aspartate aminotransferase; Benzoquinones - pharmacology; Beta-aminoisobutyric acid; Cardiomyopathy; Chemical compounds; CK-MB; Congestive heart failure; Creatine; Creatine kinase; Diabetes; Diabetes mellitus; Diabetes Mellitus, Experimental - drug therapy; Diabetes Mellitus, Experimental - metabolism; Diabetes Mellitus, Experimental - pathology; Diabetic Cardiomyopathies - drug therapy; Diabetic Cardiomyopathies - metabolism; Diabetic Cardiomyopathies - pathology; Diabetic cardiomyopathy; Fibrosis; Glutathione; Inflammation; Kinases; L-Lactate dehydrogenase; Lactate dehydrogenase; Lactic acid; Male; Malondialdehyde; Myocardium; Pharmacology; Rats; Rats, Sprague-Dawley; Streptozocin; Streptozotocin; Thymoquinone; Tumor necrosis factor-α
• ISSN: 0040-8166; 1532-3072
• DOI: 10.1016/j.tice.2021.101582

•Diabetic cardiomyopathy is a cardiac dysfunction observed in diabetic patients that can lead to heart failure.•No specific treatment has yet been tested in DCM.•Oxidative damage, proinflammatory responses, and apoptosis are key players in pathogenesis of diabetic cardiomyopathy.•Diabetes increase in the expression of Tnf-α, the rate of fibrosis and apoptosis in myocardium.•Thymoquinone and beta-aminoisobutyric can be used to treat diabetic cardiomyopathy. Diabetic cardiomyopathy (DCM) is a cardiac dysfunction observed in a patient with diabetes that may lead to heart failure. No specific treatment has yet been tested in DCM. Therefore, in this study, it was investigated that the potential of thymoquinone (TYM) and beta-aminoisobutyric acid (BAIBA) to treat DCM. Five groups (n = 7) were formed, namely control, diabetes, TYM, BAIBA and TYM + BAIBA, with a random selection from 35 adult male rats. Diabetes mellitus was induced by intraperitoneal administration of 50 mg/kg streptozotocin to all groups except the control. After establishing experimental diabetes, TYM (20 mg/kg/day) and BAIBA (100 mg/kg/day) were administered alone or in combination with other groups other than the control and diabetes groups for five weeks by gavage. Serum aspartate aminotransferase, lactate dehydrogenase, creatine kinase-MB, and tissue malondialdehyde levels increased significantly, and tissue glutathione levels decreased in the diabetes group compared to the control group. An increase in the expression of tumor necrosis factor-α in the myocardium and the rate of fibrosis and apoptosis were found in the histopathological analysis. In the TYM and BAIBA groups, all pathological changes observed in the diabetes group improved significantly. The therapeutic effects of these agents on DCM are probably due to their antihyperglycemic, antidiabetic, antioxidant, and anti-inflammatory effects. The present results suggested that TYM and BAIBA have the potential therapeutic effects on DCM that were used alone or combined.